Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

TOTEM
Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

TOTEM: Study Design

**Background**: 12-week, multicenter, open-label, randomized trial of substituting the NRTI backbone with TDF-FTC for virologically suppressed patients with elevated lipids.

**Inclusion Criteria (n = 91)**
- Adults with HIV infection
- HIV RNA <400 copies/mL for ≥6 months
- Elevated fasting LDL or triglycerides
- Receiving 2 NRTI’s (not TDF-FTC) plus an NNRTI or boosted PI

**Treatment Arms (Randomized 1:1)**
- Replace NRTI backbone with TDF-FTC
- Continue current regimen

**Study Design: TOTEM**

- TDF-FTC + Continue 3rd Agent (n = 46)
- Continue Current ART (n = 45)

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine
TOTEM: Results

Week 12: Change in Plasma Lipids from Baseline

Conclusions: “Switching to tenofovir disoproxil fumarate + emtricitabine in dyslipidaemic HIV-infected patients improves triglycerides and LDL-cholesterol.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*